School of Chemical and Biotechnology, SASTRA Deemed University, Tirumalaisamudram, Thanjavur, Tamil Nadu, India.
Vascular Biology Lab, SASTRA Deemed University, Tirumalaisamudram, Thanjavur, Tamil Nadu, India.
Naunyn Schmiedebergs Arch Pharmacol. 2022 May;395(5):547-561. doi: 10.1007/s00210-022-02204-8. Epub 2022 Feb 8.
Renal ischemic reperfusion (IR) injury is one of the major source of mortality and morbidity associated with acute kidney injury (AKI). Several flavonoids have shown to be renal protective against many nephrotoxic agents causing AKI. Fisetin, a promising flavonoid, is effective in the management of septic AKI, expected to ameliorate renal IR injury. The present study aimed to generate evidence for fisetin-mediated renal protection against IR injury. Male Wistar rats of 200-250 g were subjected to IR protocol by performing bilateral clamping for 45 min and reperfusion for 24 h. Fisetin was administrated 30 min (20 mg/kg b.wt, ip) before the surgery. Renal injury was evaluated by measuring the biomarkers in plasma, examining the ultra-structure of the kidney, and analyzing the apoptotic changes. Oxidative stress, antioxidant levels, and mitochondrial function were analyzed in the renal tissue. Fisetin administration significantly reduced the renal damages associated with IR by improving estimated glomerular filtration rate (eGFR: IR-0.35 ml/min, F_IR-9.03 ml/min), reducing plasma creatinine level (IR-2.2 mg/dl, F_IR-0.92 mg/dl), and lowering urinary albumin/creatinine ratio (IR-6.09 F_IR-2.16), caspase activity, decreased DNA fragmentation and reduced tubular injury score (IR- 11 F_IR-6.5). At the cellular level, fisetin significantly reduced renal oxidative stress and augmented the antioxidant levels. Fisetin was found to preserve mitochondrial electron transport chain activities and improved the ATP producing capacity in the renal tissue upon IR injury. Fisetin pretreatment attenuates renal IR injury by improving renal function, reducing the renal injury mediated by apoptosis, reducing free radical release, and augmenting mitochondrial function.
肾缺血再灌注(IR)损伤是与急性肾损伤(AKI)相关的主要死亡和发病原因之一。几种类黄酮已被证明对许多引起 AKI 的肾毒性物质具有肾保护作用。非瑟酮是一种很有前途的类黄酮,可有效治疗脓毒症 AKI,有望改善肾 IR 损伤。本研究旨在为非瑟酮介导的肾保护作用对抗 IR 损伤提供证据。200-250g 的雄性 Wistar 大鼠通过双侧夹闭 45 分钟并再灌注 24 小时来进行 IR 方案。在手术前 30 分钟(20mg/kg b.wt,ip)给予非瑟酮。通过测量血浆中的生物标志物、检查肾脏的超微结构以及分析细胞凋亡变化来评估肾损伤。在肾组织中分析氧化应激、抗氧化水平和线粒体功能。非瑟酮给药通过改善估计肾小球滤过率(eGFR:IR-0.35ml/min,F_IR-9.03ml/min)、降低血浆肌酐水平(IR-2.2mg/dl,F_IR-0.92mg/dl)和降低尿白蛋白/肌酐比值(IR-6.09 F_IR-2.16)来显著减轻与 IR 相关的肾损伤,降低半胱天冬酶活性、减少 DNA 片段化并降低管状损伤评分(IR-11 F_IR-6.5)。在细胞水平上,非瑟酮显著降低了肾氧化应激并增加了抗氧化水平。发现非瑟酮可维持线粒体电子传递链的活性并在 IR 损伤时提高肾组织中产生 ATP 的能力。非瑟酮预处理通过改善肾功能、减少凋亡介导的肾损伤、减少自由基释放和增加线粒体功能来减轻肾 IR 损伤。